Research of the adaptive resistance to targeted therapies directed at the RAS-ERK signaling pathway has demonstrated the role of integrin, FAK, and an intact actin cytoskeleton in a subset of metastatic triple-negative breast cancer cells. This evidence concerns the gene MAPK1 and triple-negative breast carcinoma.